MARKET

DRRX

DRRX

DURECT
NASDAQ
0.6476
-0.0134
-2.03%
Opening 13:40 12/07 EST
OPEN
0.6499
PREV CLOSE
0.6610
HIGH
0.6612
LOW
0.6350
VOLUME
159.53K
TURNOVER
0
52 WEEK HIGH
9.50
52 WEEK LOW
0.4703
MARKET CAP
19.32M
P/E (TTM)
-0.4230
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DRRX last week (1127-1201)?
Weekly Report · 3d ago
DURECT: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 6d ago
Weekly Report: what happened at DRRX last week (1120-1124)?
Weekly Report · 11/27 12:27
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.
Benzinga · 11/22 21:31
Weekly Report: what happened at DRRX last week (1113-1117)?
Weekly Report · 11/20 12:23
Analysts Conflicted on These Healthcare Names: Taysha Gene Therapies (TSHA) and Durect (DRRX)
Analysts have reiterated buy ratings on taysha gene therapies and durect. Chardan capital's geulah livshits reiterated a buy rating on the healthcare sector stock today. Jonestrading analyst sean kim phd maintained a hold rating on durec today.
TipRanks · 11/15 13:10
Analysts Offer Insights on Healthcare Companies: NexGel Inc (NXGL), Taysha Gene Therapies (TSHA) and Durect (DRRX)
maxim group reiterated a buy rating on nexgel inc. With a price target of $6.00. Naz rahman from maxim group covers the healthcare sector. Taysha gene therapies and durect also have new ratings from maxim and other analysts in the sector.
TipRanks · 11/15 13:02
DURECT: Quarterly report
Press release · 11/15 07:59
More
About DRRX
Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology.

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.